牛牛AI助理已提取核心訊息
Senti Biosciences, Inc. (SNTI.US) reported that its Chief Medical & Development Officer, Rajangam Kanya, was granted 101,000 shares of common stock on February 1, 2024. The transaction, which was completed on the same day, was a grant with no cost associated with the acquisition. Following this transaction, Kanya directly holds a total of 101,000 shares in the company. The grant is part of the company's compensation strategy for its executives and is indicative of the company's commitment to aligning the interests of its leadership with those of its shareholders.
Senti Biosciences, Inc. (SNTI.US) reported that its Chief Medical & Development Officer, Rajangam Kanya, was granted 101,000 shares of common stock on February 1, 2024. The transaction, which was completed on the same day, was a grant with no cost associated with the acquisition. Following this transaction, Kanya directly holds a total of 101,000 shares in the company. The grant is part of the company's compensation strategy for its executives and is indicative of the company's commitment to aligning the interests of its leadership with those of its shareholders.
Senti Biosciences, Inc.（SNTI.US）報告稱，其首席醫療與開發官拉詹甘·坎亞於2024年2月1日獲得了10.1萬股普通股。該交易於當天完成，是一筆贈款，與收購無關。在這筆交易之後，Kanya直接持有該公司總共10.1萬股股份。該補助金是公司高管薪酬戰略的一部分，表明公司致力於協調其領導層的利益與股東的利益。
Senti Biosciences, Inc.（SNTI.US）報告稱，其首席醫療與開發官拉詹甘·坎亞於2024年2月1日獲得了10.1萬股普通股。該交易於當天完成，是一筆贈款，與收購無關。在這筆交易之後，Kanya直接持有該公司總共10.1萬股股份。該補助金是公司高管薪酬戰略的一部分，表明公司致力於協調其領導層的利益與股東的利益。
有用
沒用